ClinicalTrials.gg
RecruitingNCT07112924CCM OPEN HFUpdated Oct 27, 2026

CCM OPEN HF Registry

An observational study in Heart Failure, sponsored by Impulse Dynamics. Recruiting at 30 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Impulse Dynamics · Observational

How we know · 2 judgments

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Oct 27, 2026Site recruiting status changed2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
5,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Heart Failure by Impulse Dynamics — 4 open to participants now, 6 under way, none of them phase 3. Heart Failure · Impulse Dynamics.

Started
2025
with 2 others
Observational
4 of 11
3 open now
Registered
10th of 11
by date

Among the 11 studies in Heart Failure by Impulse Dynamics, this one is one of 3 that started in 2025, is one of 4 observational ones, and was the 10th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

4 of the 11 studies in Heart Failure by Impulse Dynamics are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Heart Failure by Impulse Dynamics, or all of them as a file.
02

Study summary

The registry has been designed to evaluate the long-term safety and efficacy of CCM therapy in a real-world setting.

Read the detailed description

This is a global, prospective and retrospective, multicenter, single-arm, observational study intended to include patients who will receive/have received CCM therapy with an Impulse Dynamics system, including future CCM technologies (e.g. CCM-D), for a follow-up period of at least 5 years.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart Failure
  • CCM
  • Optimizer
  • Implantable Pulse Generator
  • FDA Approved
  • Heart Failure Hospitalization
  • Ischemic vs non-ischemic
  • CRT non-responders
  • Patients with concomitant devices
  • Patients with wide, intermediate, narrow QRS
  • Patients with cardiac amyloidosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who will receive/have received CCM therapy with an Impulse Dynamics system

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have /will be implanted with Impulse Dynamics CCM technologies (e.g. CCM or CCM-D when available) as determined by investigators
  • Willing and able to provide , including for use of data for research purposes (e.g. publication, sub-studies/sub-analyses)

Exclusion criteria

Exclusion Criteria:

  • Noncompliant patients (e.g. for follow-up visits, medication, etc.) as determined by investigators.
  • Subjects with a mechanical tricuspid valve
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
5,500 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Retrospective Cohort

    Prospective Cohort

  • Hybrid (Retrospective-Prospective) Cohort

    Patients who will receive/ have received CCM therapy with an Impulse Dynamics devices

  • Prospective Cohort

    Patients who will receive CCM therapy with an Impulse Dynamics devices

06

What researchers measure

Primary outcomes

  1. Assess CCM's effect on the rate and length of stay of heart failure (HF) hospitalizations

    Change in the HF hospitalization / urgent HF visit rate and hospital length of stay from 1 year prior to 1 year following index implantation.

    Time frame: 1 Year

  2. Demonstrate the long-term safety of CCM therapy in a real-world setting, by assessing the rate of device- or procedure-related complications.

    Rate of freedom from a composite of device- or procedure-related complication post-index implantation procedure. Serious procedure related complications occurring through the end of 30 days following the index procedure. Serious CCM device-related complications\* occurring through the end of 1-year following the index procedure. \* excluding lead-related complications

    Time frame: 5 Years

Secondary outcomes

  1. Assess CCM's effect on clinical outcomes

    Composite of all-cause mortality, heart-failure hospitalizations/urgent heart failure visits, progression to LVAD/heart transplant 1-, 3-, and 5-years following the index procedure.

    Time frame: 5 Years

  2. Assess CCM's effect on mortality (all-cause, cardiovascular, and heart failure related)

    All-cause: Observed mortality will be compared to predicted mortality for the subject group according to the Seattle Heart Failure Model (SHFM) and/or Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) at 1-, 3-, and 5-years following the index procedure. Cardiovascular related mortality will be assessed at 1-, 3-, and 5-years following the index procedure.

    Time frame: 5 Year

  3. Assess CCM's effect on healthy days at home (HDAH)

    Assessment of HDAH 1 year prior to 3 years following index implantation.

    Time frame: 3 Years

  4. Assess CCM's effect on functional capacity

    Change in NYHA Functional Class from baseline to 1-, 2-, 3-, 4-, and 5-years following the index procedure. Change in 6-minute walk test (6MWT) from baseline to 1 year following the index procedure.

    Time frame: 5 Year

  5. Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Change in KCCQ score from baseline to 6 months and 1 year after the index procedure. Scores range from 0 to 100, with higher scores showing better health status and lower scores showing worsen health status.

    Time frame: 1 Year

  6. Assess CCM's effect cardiovascular reverse remodeling

    Change in LVEF, LVESV, LVEDV from baseline to 1-, 2-, 3-, 4-, and 5-years following the index procedure.

    Time frame: 5 Year

  7. Assess CCM's effect QRS duration

    Change in QRS duration from baseline to 1-, 2-, 3-, 4-, and 5-years following the index procedure.

    Time frame: 5 Years

  8. Assess CCM's systemic effects

    Change in eGFR and BNP from baseline to 1-, 2-, 3-, 4-, and 5-years following the index procedure.

    Time frame: 5 Years

  9. Assess long-term CCM device-related adverse events and lead related events

    An assessment of the incidence of CCM device-related serious complications and non-serious CCM-device-related observations occurring during the 5-year period following the index procedure.

    Time frame: 5 Years

  10. Assess the dose response of CCM therapy

    Correlation of CCM % and milliamp (mA) delivered with clinical outcomes and health status

    Time frame: 5 Year

  11. Evaluate subject battery charging compliance

    Assess overall battery charging compliance defined as 60 minutes of charging per 10-day period between charging sessions (Expressed as percentage of compliant charging periods per subject over time e.g., number of compliant charging cycles ÷ total expected cycles × 100%).

    Time frame: 5 Year

  12. Assess the effect of ancillary equipment on clinical outcomes

    Impact of ancillary equipment on clinical outcomes at 1- 2-, 3-, 4-, and 5-years following the index procedure. Including but not limited to: Lead type: style-driven lead, lumenless lead Guiding sheath/catheter

    Time frame: 5 Years

  13. Assess CCM clinical outcomes by subject sub-groups

    Assess CCM effectiveness at various timepoints in sub-groups of interest, including but not limited to: Male vs female \<65 vs ≥ 65-year-old Ischemic vs non-ischemic CRT non-responders Patients with concomitant devices (e.g. CRT, pacemaker, LBBP) Patients with wide, intermediate, narrow QRS Patients with cardiac amyloidosis

    Time frame: 5 Years

07

Study locations

10 of 30 sites recruiting
  • Cardiovascular Associates of Mesa
    Mesa, Arizona 85206, United States
    Recruiting
    • Adam Gitkin, MS · Contactagitkin@cvam.com · 480-641-5400
    • Ambrose Panico, DO · Principal investigator
  • University of Arizona and Banner University Medical Center Phoenix
    Phoenix, Arizona 85006, United States
    Not yet recruiting
  • HonorHealth Research Institute
    Phoenix, Arizona 85020, United States
    Not yet recruiting
  • Peak Heart and Vascular
    Surprise, Arizona 85378, United States
    Recruiting
    • Neha Joshi · Contactnjoshi@onyxclinical.com · 602-830-2626
    • Andy Tran, MD · Principal investigator
    • Truong Duong, MD · Sub investigator
  • AdventHealth Orlando
    Orlando, Florida 32803, United States
    Not yet recruiting
  • AdventHealth Tampa
    Tampa, Florida 33613, United States
    Not yet recruiting
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
    Not yet recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02144, United States
    Recruiting
    • Payton Black · Contactpblack3@mgh.harvard.edu · 617-643-1972
    • Chris Azzam · Contactcazzam@mgh.harvard.edu · 617-643-9621
    • Theofanie Mela, MD · Principal investigator
    • Jagmeet Singh, MD · Sub investigator
    • Dingxin Qin, MD · Sub investigator
    • Aneesh Bapat, MD · Sub investigator
    • Bill Hucker, MD · Sub investigator
    • Kevin Heist, MD · Sub investigator
    • A Abdul, MD · Sub investigator
    • Eric Mills, MD · Sub investigator
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
    Not yet recruiting
    • Mamid Ghanbari, MD · Principal investigator
    • Kirsta Bray, MD · Sub investigator
    • Ian Pizzo, MD · Sub investigator
  • Henry Ford Providence Hospital
    Novi, Michigan 48374, United States
    Not yet recruiting
    • Candice Edillo · Contactcedillo1@hfhs.org · 248-849-3197
    • Nathan Foster, MD · Principal investigator
  • Trinity Ann Arbor d/b/a Michigan Heart Ann Arbor
    Ypsilanti, Michigan 48197, United States
    Not yet recruiting
  • Minneapolis Heart Institute Research Foundation
    Minneapolis, Minnesota 55407, United States
    Not yet recruiting
  • Saint Luke's Hospital Mid America Heart Institute
    Kansas City, Missouri 64111, United States
    Not yet recruiting
  • Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
    Not yet recruiting
    • Kendra Black · Contactktraylor@saint-lukes.org · 816-932-0394
    • Amada Huffman · Contactahuffman@saint-lukes.org · 816-932-0391
    • Timothy Fendler, MD · Principal investigator
    • Daniel Steinhaus, MD · Sub investigator
    • Sanjaya Gupta, MD · Sub investigator
    • Jose Aguilera, MD · Sub investigator
  • Cardiovascular Specialists of New England Research Foundation
    Londonderry, New Hampshire 03053, United States
    Recruiting
    • Jennifer Driscoll · Contactjennifer.driscoll@csofne.com · 603-323-0883
    • David Chang, MD · Principal investigator
    • Jamie Kim, MD · Sub investigator
    • Jinu John, MD · Sub investigator
    • Jeanney Lew, MD · Sub investigator
  • Deborah Heart and Lung Center
    Browns Mills, New Jersey 08015, United States
    Not yet recruiting
    • Lout Lewis · ContactLewisL@Deborah.org · 609-893-1200
    • Andrew McElvarr · ContactMcelavarra@deborah.org · 609-893-1200
    • Raffaele Corbisiero, MD · Principal investigator
    • G Rojas-Marte, MD · Sub investigator
    • J Krathen, DO · Sub investigator
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
    Not yet recruiting
  • Heart House
    Haddon Heights, New Jersey 08035, United States
    Recruiting
    • Elizabeth Watson · Contactewatson@hearthousenj.com · 856-546-3003
    • Ann Davison · Contactadavison@hearthousenj.com · 856-546-3003
    • John Costello, MD · Principal investigator
    • Steve Levi, MD · Sub investigator
    • Jet Vojinika, MD · Sub investigator
  • Rutgers New Jersey Medical School & University Hospital
    Newark, New Jersey 07103, United States
    Not yet recruiting
    • Adel Aly · Contactaaa531@njms.rutgers.edu · 973-972-1054
    • Hector Salcedo · Contacthrs60@njms.rutgers.edu
    • Amed Aziz, MD · Principal investigator
    • Pallavi Solanski, MD · Sub investigator
    • Luka Petrovic, MD · Sub investigator
  • Oklahoma Heart Hospital Research Foundation
    Oklahoma City, Oklahoma 73120, United States
    Recruiting
    • Rebecca Straily · Contactrstraily@okheart.com · 405-608-1287
    • Charles Te, MD · Principal investigator
  • Providence St. Vincent Medical Center
    Portland, Oregon 97225, United States
    Not yet recruiting
  • Legacy Medical Group Cardiology
    Portland, Oregon 98686, United States
    Not yet recruiting
    • Kristin Hickey · Contactkhickey@lhs.org · 503-413-4365
    • Brendan Daly, MD · Principal investigator
    • Robert Murdock, MD · Sub investigator
  • Reading Hospital
    West Reading, Pennsylvania 19611, United States
    Not yet recruiting
  • The Stern Cardiovascular Foundation, Inc
    Germantown, Tennessee 38138, United States
    Recruiting
    • Kari Fondren · Contactkari.fondren@sterncardio.com · 901-271-4062
    • Steven Gubin, MD · Principal investigator
    • Eric Johnson, MD · Sub investigator
    • David Lan, MD · Sub investigator
  • David Turbay, MD
    El Paso, Texas 79905, United States
    Recruiting
  • Texan Cardiovascular Institute
    El Paso, Texas 79936, United States
    Not yet recruiting
  • CHRISTUS Trinity Mother Frances Health System
    Tyler, Texas 75701, United States
    Recruiting
  • Centra Health, Inc. dba Stroobants Cardiovascular Center
    Lynchburg, Virginia 24501, United States
    Recruiting
  • PeaceHealth Southwest Medical Center
    Vancouver, Washington 98644, United States
    Not yet recruiting
  • Advocate Aurora Health-St. Lukes
    Milwaukee, Wisconsin 53215, United States
    Not yet recruiting
    • Rebecca Hough · Contactrebecca.hough@aah.org · 262-248-5430
    • Imran Niazi, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — The data are part of an ongoing commercial development program and are considered proprietary at this stage.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Aug 2035, 117 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2025
First posted
Aug 8, 2025
StartActual
Nov 1, 2025
Primary completionEst.
Aug 15, 2035
CompletionEst.
Aug 1, 2036
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Cardiovascular Specialists of New England Research Foundation · Londonderry, United StatesNot yet recruiting→Recruiting
  • CHRISTUS Trinity Mother Frances Health System · Tyler, United StatesNot yet recruiting→Recruiting
Show 2 added (2 United States)
  • Heart House · Haddon Heights, United States
  • Oklahoma Heart Hospital Research Foundation · Oklahoma City, United States
Oct 27, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Peak Heart and Vascular · Surprise, United StatesContact t•••@axsendoclinical.com→n•••@onyxclinical.com · •••2626
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    2 sites added. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Cardiovascular Specialists of New England Research Foundation · Londonderry, United StatesNot yet recruiting→Recruiting
    • CHRISTUS Trinity Mother Frances Health System · Tyler, United StatesNot yet recruiting→Recruiting
    Show 2 added (2 United States)
    • Heart House · Haddon Heights, United States
    • Oklahoma Heart Hospital Research Foundation · Oklahoma City, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Peak Heart and Vascular · Surprise, United StatesContact t•••@axsendoclinical.com→n•••@onyxclinical.com · •••2626
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07112924
Lead sponsor
Impulse Dynamics
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Nov 1, 2025
Primary completion
Aug 15, 2035 (estimated)
Completion
Aug 1, 2036 (estimated)
Last update
Oct 27, 2026

Study contacts

Karl Van Wygerden
Contact
kvanwygerden@impulsedynamics.com
856-642-9933
Erika Mednick
Contact
emednick@impulsedynamics.com
8454990412
Anthony Hong
study director · Impulse Dynamics
Lee Ming Boo
study director · Impulse Dynamics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion